Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Cornell Pochily Investment Advisors Inc.

Cornell Pochily Investment Advisors Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,708 shares of the biopharmaceutical company’s stock after buying an additional 1,642 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Gilead Sciences were worth $1,192,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of GILD. PCA Investment Advisory Services Inc. purchased a new position in shares of Gilead Sciences during the second quarter worth about $25,000. OFI Invest Asset Management purchased a new position in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Tompkins Financial Corp lifted its stake in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Union Savings Bank purchased a new stake in shares of Gilead Sciences in the second quarter valued at $29,000. Finally, Fortitude Family Office LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Royal Bank of Canada decreased their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Cantor Fitzgerald cut their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Barclays reduced their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and a consensus target price of $85.36.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at $8,709,586.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. Insiders have sold 15,242 shares of company stock valued at $1,277,726 in the last quarter. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $0.41 during mid-day trading on Thursday, hitting $73.42. 1,045,274 shares of the company’s stock traded hands, compared to its average volume of 7,491,144. The company has a market cap of $91.41 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.18. The firm has a 50 day moving average price of $75.38 and a 200 day moving average price of $77.32. Gilead Sciences, Inc. has a one year low of $71.37 and a one year high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same period in the prior year, the company posted $1.67 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.07 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.20%. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.